

PATENT
4644US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

van Ostade et al.

Serial No.: To be assigned

Filed: January 26, 2001

For: EUKARYOTIC CELL-BASED GENE
INTERACTION CLONING

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 4644US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL 74053249105

Date of Deposit with USPS: January 26, 2001

Person making Deposit: Jared Turner

JC841 U.S. PTO
09/771425
01/26/01

Statement under 37 C.F.R. § 1.821(f)

Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Jarett K. Abramson, an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the SEQUENCE LISTING, as well as the enclosed copy of the SEQUENCE LISTING in computer readable form (CRF), are in compliance with the requirements of 37 C.F.R. §§ 1.821 through 1.825.
2. The enclosed copy of the SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the SEQUENCE LISTING.

2. The enclosed copy of the SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the SEQUENCE LISTING.

Respectfully submitted,



Jarett K. Abramson
Registration No. P-47,376
Attorney for Applicants
TRASK BRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110
Telephone: (801) 532-1922

Date: January 22, 2001

N:\2676\4644\sequence statement.wpd

SEQUENCE LISTING

<110> van Ostade, Xaveer
Vandekerckhove, Joel Stefaan
Verhee, Annick
Tavernier, Jan

<120> EUKARYOTIC CELL-BASED GENE INTERACTION CLONING

<130> 2676-4644US

<150> PCT/EP99/05491

<151> 1999-07-27

<150> EP 98202528.0

<151> 1998-07-28

<160> 19

<170> PatentIn version 3.0

<210> 1

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_feature

<223> Description of Artificial Sequence: MBU-O-37 hIL5Ralpha nt.
251-26

<400> 1

gctggtagca tgatcatcgt ggcgcgatg
28

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_feature

<223> Description of Artificial Sequence: MBU-O-38 hIL5Ralpha nt.
1272-1

25

<400> 2

ctctctcaag ggcttgtgtt c
21

<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: MBU-O-39 hbetac nt.29-4
9

<400> 3
gctggtacca tgggtgctggc ccaggggctg
30

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: MBU-O-40 hbetac nt.1343
-1322

<400> 4
cgactcgggtg tcccaggagc g
21

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: MBU-O-41 hIFNa1 nt.138
4-1403

<400> 5
aaaatttggc ttatagttgg
20

<210> 6
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> MBU-O-42 hIFNaR1 nt.1743-1764

<400> 6
 cgtctcgagg ttcatttctg gtcatacaaa g
 31

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-43 hIFNaR2-1 nt.7
 93-812

<400> 7
 aaaataggag gaataattac
 20

<210> 8
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-44 hIFNaR2-1 nt.1
 210-12
 3

<400> 8
 cgtctcgaga cataataaaa cttaatcact ggg
 33

<210> 9

<211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-45 hIFNaR2-2 nt.1
 626-16
 0

<400> 9
 cgtctcgaga tagtttttggga gtcattctc
 28

<210> 10
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-278 PacI mutagene
 sis in
 IL-5Ralpha/IFNaR2-

<400> 10
 cacaagccct tgagagagtt aattaaaata ggaggaataa ttactg
 46

<210> 11
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-279 PacI mutagene
 sis in
 IL-5Ralpha/IFNaR2-

<400> 11
 cagtaattat tcctcctatt ttaattaact ctctcaaggg cttgtg
 46

<210> 12

<211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-280 PacI mutagene
 sis in
 beta/IFNaR

<400> 12
 cctgggacac cgagtcgtta attaaaattt ggcttatagt tgg
 43

<210> 13
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-281 PacI mutagene
 sis in
 beta/IFNaR

<400> 13
 ccaactataa gccaaatttt aattaacgac tcggtgtccc agg
 43

<210> 14
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <223> Description of Artificial Sequence: MBU-O-167 hEPO-R primer
 nt.10

<400> 14
 cgggggtacca tggaccacct cggggcgctcc
 30

<210> 15

<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: MBU-O-308 hEPO-R primer
nt.87

<400> 15
cccttaatta agtccaggtc gctaggcgtc ag
32

<210> 16
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: MBU-O-187 Linker for pM
ET7-MC

<400> 16
tcgactcaga tcttcgatat ctcggtaacc tcaccgggtc ctcgagtct
49

<210> 17
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: MBU-O-188 Linker for pM
ET7-MC

<400> 17
ctagagactc gaggaaccgg tgagggttacc gagatatcga agatctgag
49

<210> 18

<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: forward primer

<400> 18
ggaattcgcc aggcgccacc atgggggtgc acgaatgtcc tg
42

<210> 19
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<223> Description of Artificial Sequence: reverse primer

<400> 19
gcctcgagtc atctgtcccc tctcctgcag
30